{
    "abstract": "Background: Hepatitis B virus infection remains an important public health problem in the United States. Currently approved alum-adjuvanted vaccines require three doses and have reduced immunogenicity in adults, particularly in those who have diabetes mellitus, or are older, male, obese, or who smoke. Methods: Phase 3 observer\u2013blinded, randomized (2:1 HBsAg-1018 [HEPLISAV-B\u2122]:HBsAg-Eng [Engerix-B\u00ae]), active\u2013controlled trial in adults 18\u201370 years of age. HBsAg-1018 was administered intramuscularly at weeks 0 and 4 and placebo at week 24 and HBsAg-Eng at weeks 0, 4, and 24. The primary immunogenicity endpoint assessed the noninferiority of the seroprotection rate at week 28 in participants with type 2 diabetes mellitus. Secondary endpoints included seroprotection rates in the total trial population and by age, sex, body mass index, and smoking status. Results: Among 8374 participants randomized, 961 participants in the per-protocol population had type 2 diabetes mellitus. In diabetes participants, the seroprotection rate in the HBsAg-1018 group at week 28 was 90.0%, compared with 65.1% in the HBsAg-Eng group, with a difference of 24.9% (95% CI: 19.3%, 30.7%), which met the prospectively-defined criteria for noninferiority and statistical significance. In the total study per-protocol population (N = 6826) and each pre-specified subpopulation, the seroprotection rate in the HBsAg-1018 group was statistically significantly higher than in the HBsAg-Eng group. Conclusion: Two doses of HBsAg-1018, administered over 4 weeks, induced significantly higher seroprotection rates than three doses of HBsAg-Eng, given over 24 weeks, in adults with factors known to reduce the immune response to hepatitis B vaccines as well as in those without those factors. With fewer doses in a shorter time, and greater immunogenicity, HBsAg-1018 has the potential to significantly improve protection against hepatitis B in adults at risk for hepatitis B infection. Trial Registration clinicaltrials.gov Identifier: NCT02117934.",
    "author_highlights": [
        {
            "endOffset": 17125,
            "sentence": "Phase 3 trial of an investigational 2 dose hepatitis B vaccine in diabetes mellitus.",
            "startOffset": 17041
        },
        {
            "endOffset": 17213,
            "sentence": "2 doses of HBsAg-1018 induced significantly higher seroprotection rates than HBsAg-Eng.",
            "startOffset": 17126
        },
        {
            "endOffset": 17298,
            "sentence": "HBsAg-1018 demonstrated better consistency of SPRs in subpopulations than HBsAg-Eng.",
            "startOffset": 17214
        }
    ],
    "bib_entries": {
        "b0005": null,
        "b0010": {
            "authors": [
                {
                    "first": "Kris V.",
                    "initial": "K.V.",
                    "last": "Kowdley"
                },
                {
                    "first": "Chia C.",
                    "initial": "C.C.",
                    "last": "Wang"
                },
                {
                    "first": "Sue",
                    "initial": "S.",
                    "last": "Welch"
                },
                {
                    "first": "Henry",
                    "initial": "H.",
                    "last": "Roberts"
                },
                {
                    "first": "Carol L.",
                    "initial": "C.L.",
                    "last": "Brosgart"
                }
            ],
            "doi": "10.1002/hep.24804",
            "firstpage": "422",
            "issn": "02709139",
            "lastpage": "433",
            "pmid": "22105832",
            "pub_year": 2012,
            "title": "Prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of origin",
            "volume": "56"
        },
        "b0015": null,
        "b0020": null,
        "b0025": {
            "authors": [
                {
                    "first": "Aaron M.",
                    "initial": "A.M.",
                    "last": "Harris"
                },
                {
                    "first": "Kashif",
                    "initial": "K.",
                    "last": "Iqbal"
                },
                {
                    "first": "Sarah",
                    "initial": "S.",
                    "last": "Schillie"
                },
                {
                    "first": "James",
                    "initial": "J.",
                    "last": "Britton"
                },
                {
                    "first": "Marion A.",
                    "initial": "M.A.",
                    "last": "Kainer"
                },
                {
                    "first": "Stacy",
                    "initial": "S.",
                    "last": "Tressler"
                },
                {
                    "first": "Claudia",
                    "initial": "C.",
                    "last": "Vellozzi"
                }
            ],
            "doi": "10.15585/mmwr.mm6503a2",
            "firstpage": "47",
            "issn": "01492195",
            "lastpage": "50",
            "pmid": "26821369",
            "pub_year": 2016,
            "title": "Increases in acute hepatitis B virus infections \u2014 Kentucky, Tennessee, and West Virginia, 2006\u20132013",
            "volume": "65"
        },
        "b0030": {
            "authors": [
                {
                    "first": "Matthew F.",
                    "initial": "M.F.",
                    "last": "Daley"
                },
                {
                    "first": "Karen A.",
                    "initial": "K.A.",
                    "last": "Hennessey"
                },
                {
                    "first": "Cindy M.",
                    "initial": "C.M.",
                    "last": "Weinbaum"
                },
                {
                    "first": "Shannon",
                    "initial": "S.",
                    "last": "Stokley"
                },
                {
                    "first": "Laura P.",
                    "initial": "L.P.",
                    "last": "Hurley"
                },
                {
                    "first": "Lori A.",
                    "initial": "L.A.",
                    "last": "Crane"
                },
                {
                    "first": "Brenda L.",
                    "initial": "B.L.",
                    "last": "Beaty"
                },
                {
                    "first": "Jennifer C.",
                    "initial": "J.C.",
                    "last": "Barrow"
                },
                {
                    "first": "Christine I.",
                    "initial": "C.I.",
                    "last": "Babbel"
                },
                {
                    "first": "L. Miriam",
                    "initial": "L.M.",
                    "last": "Dickinson"
                },
                {
                    "first": "Allison",
                    "initial": "A.",
                    "last": "Kempe"
                }
            ],
            "doi": "10.1016/j.amepre.2009.01.037",
            "firstpage": "491",
            "issn": "07493797",
            "lastpage": "496",
            "pmid": "19362798",
            "pub_year": 2009,
            "title": "Physician Practices Regarding Adult Hepatitis B Vaccination. A National Survey",
            "volume": "36"
        },
        "b0035": {
            "authors": [
                {
                    "first": "F.",
                    "initial": "F.",
                    "last": "Ladak"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Gjelsvik"
                },
                {
                    "first": "E.",
                    "initial": "E.",
                    "last": "Feller"
                },
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "Rosenthal"
                },
                {
                    "first": "B. T.",
                    "initial": "B.T.",
                    "last": "Montague"
                }
            ],
            "doi": "10.1007/s15010-011-0241-2",
            "firstpage": "405",
            "issn": "03008126",
            "lastpage": "413",
            "pmid": "22237474",
            "pub_year": 2012,
            "title": "Hepatitis B in the United States: Ongoing missed opportunities for hepatitis B vaccination, evidence from the Behavioral Risk Factor Surveillance Survey, 2007",
            "volume": "40"
        },
        "b0040": {
            "authors": [
                {
                    "first": "David J.",
                    "initial": "D.J.",
                    "last": "Weber"
                },
                {
                    "first": "William A.",
                    "initial": "W.A.",
                    "last": "Rutala"
                },
                {
                    "first": "Gregory P.",
                    "initial": "G.P.",
                    "last": "Samsa"
                },
                {
                    "first": "Jane E.",
                    "initial": "J.E.",
                    "last": "Santimaw"
                },
                {
                    "first": "Stanley M.",
                    "initial": "S.M.",
                    "last": "Lemon"
                }
            ],
            "doi": "10.1001/jama.1985.03360220053027",
            "firstpage": "3187",
            "issn": "00987484",
            "lastpage": "3189",
            "pmid": "2933532",
            "pub_year": 1985,
            "title": "Obesity as a Predictor of Poor Antibody Response to Hepatitis B Plasma Vaccine",
            "volume": "254"
        },
        "b0045": {
            "authors": [
                {
                    "first": "D.",
                    "initial": "D.",
                    "last": "Westmoreland"
                },
                {
                    "first": "V.",
                    "initial": "V.",
                    "last": "Player"
                },
                {
                    "first": "D. C.",
                    "initial": "D.C.",
                    "last": "Heap"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Hammond"
                }
            ],
            "doi": "10.1017/S0950268800047506",
            "firstpage": "499",
            "issn": "09502688",
            "lastpage": "509",
            "pmid": "2140795",
            "pub_year": 1990,
            "title": "Immunization against hepatitis B-what can we expect?: Results of a survey of antibody response to immunization in persons \u2018at risk\u2019 of occupational exposure to hepatitis B",
            "volume": "104"
        },
        "b0050": {
            "authors": [
                {
                    "first": "P. J.",
                    "initial": "P.J.",
                    "last": "Wismans"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Van Hattum"
                },
                {
                    "first": "G. C.",
                    "initial": "G.C.",
                    "last": "De Gast"
                },
                {
                    "first": "K. P.",
                    "initial": "K.P.",
                    "last": "Bouter"
                },
                {
                    "first": "R. J.A.",
                    "initial": "R.J.A.",
                    "last": "Diepersloot"
                },
                {
                    "first": "T. J.",
                    "initial": "T.J.",
                    "last": "Maikoe"
                },
                {
                    "first": "G. C.",
                    "initial": "G.C.",
                    "last": "Mudde"
                }
            ],
            "doi": "10.1002/jmv.1890350313",
            "firstpage": "216",
            "issn": "01466615",
            "lastpage": "222",
            "pmid": "1839554",
            "pub_year": 1991,
            "title": "A prospective study of in vitro anti\u2010HBs producing B cells (spot\u2010ELISA) following primary and supplementary vaccination with a recombinant hepatitis B vaccine in insulin dependent diabetic patients and matched controls",
            "volume": "35"
        },
        "b0055": {
            "authors": [
                {
                    "first": "Aaron J.",
                    "initial": "A.J.",
                    "last": "Roome"
                },
                {
                    "first": "Stephen J.",
                    "initial": "S.J.",
                    "last": "Walsh"
                },
                {
                    "first": "Matthew L.",
                    "initial": "M.L.",
                    "last": "Cartter"
                },
                {
                    "first": "James L.",
                    "initial": "J.L.",
                    "last": "Hadler"
                }
            ],
            "doi": "10.1001/jama.1993.03510240043029",
            "firstpage": "2931",
            "issn": "00987484",
            "lastpage": "2934",
            "pmid": "8254852",
            "pub_year": 1993,
            "title": "Hepatitis B Vaccine Responsiveness in Connecticut Public Safety Personnel",
            "volume": "270"
        },
        "b0060": {
            "authors": [
                {
                    "first": "Rachel C.",
                    "initial": "R.C.",
                    "last": "Wood"
                },
                {
                    "first": "Kristine L.",
                    "initial": "K.L.",
                    "last": "Macdonald"
                },
                {
                    "first": "Karen E.",
                    "initial": "K.E.",
                    "last": "White"
                },
                {
                    "first": "Craig W.",
                    "initial": "C.W.",
                    "last": "Hedberg"
                },
                {
                    "first": "Margaret",
                    "initial": "M.",
                    "last": "Hanson"
                },
                {
                    "first": "Michael T.",
                    "initial": "M.T.",
                    "last": "Osterholm"
                }
            ],
            "doi": "10.1001/jama.1993.03510240047030",
            "firstpage": "2935",
            "issn": "00987484",
            "lastpage": "2939",
            "pmid": "8254853",
            "pub_year": 1993,
            "title": "Risk Factors for Lack of Detectable Antibody Following Hepatitis B Vaccination of Minnesota Health Care Workers",
            "volume": "270"
        },
        "b0065": {
            "authors": [
                {
                    "first": "Hans L.",
                    "initial": "H.L.",
                    "last": "Bock"
                },
                {
                    "first": "Johannes",
                    "initial": "J.",
                    "last": "Kruppenbacher"
                },
                {
                    "first": "Roland",
                    "initial": "R.",
                    "last": "S\u00e4nger"
                },
                {
                    "first": "Wilfried",
                    "initial": "W.",
                    "last": "H\u00f6bel"
                },
                {
                    "first": "Ralf",
                    "initial": "R.",
                    "last": "Clemens"
                },
                {
                    "first": "Wolfgang",
                    "initial": "W.",
                    "last": "Jilg"
                }
            ],
            "doi": "10.1001/archinte.156.19.2226",
            "firstpage": "2226",
            "issn": "00039926",
            "lastpage": "2231",
            "pmid": "8885822",
            "pub_year": 1996,
            "title": "Immunogenicity of a recombinant hepatitis B vaccine in adults",
            "volume": "156"
        },
        "b0070": {
            "authors": [
                {
                    "first": "Francisco",
                    "initial": "F.",
                    "last": "Averhoff"
                },
                {
                    "first": "Frank",
                    "initial": "F.",
                    "last": "Mahoney"
                },
                {
                    "first": "Patrick",
                    "initial": "P.",
                    "last": "Coleman"
                },
                {
                    "first": "Gary",
                    "initial": "G.",
                    "last": "Schatz"
                },
                {
                    "first": "Eugene",
                    "initial": "E.",
                    "last": "Hurwitz"
                },
                {
                    "first": "Harold",
                    "initial": "H.",
                    "last": "Margolis"
                }
            ],
            "doi": "10.1016/S0749-3797(98)00003-8",
            "firstpage": "1",
            "issn": "07493797",
            "lastpage": "8",
            "pmid": "9651632",
            "pub_year": 1998,
            "title": "Immunogenicity of hepatitis B vaccines: Implications for persons at occupational risk of hepatitis B virus infection",
            "volume": "15"
        },
        "b0075": {
            "authors": [
                {
                    "first": "Pamela",
                    "initial": "P.",
                    "last": "Rendi-Wagner"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Kundi"
                },
                {
                    "first": "Heinrich",
                    "initial": "H.",
                    "last": "Stemberger"
                },
                {
                    "first": "Gerhard",
                    "initial": "G.",
                    "last": "Wiedermann"
                },
                {
                    "first": "Heidemarie",
                    "initial": "H.",
                    "last": "Holzmann"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Hofer"
                },
                {
                    "first": "Karin",
                    "initial": "K.",
                    "last": "Wiesinger"
                },
                {
                    "first": "Herwig",
                    "initial": "H.",
                    "last": "Kollaritsch"
                }
            ],
            "doi": "10.1016/S0264-410X(00)00410-2",
            "firstpage": "2055",
            "issn": "0264410X",
            "lastpage": "2060",
            "pmid": "11228377",
            "pub_year": 2001,
            "title": "Antibody-response to three recombinant hepatitis B vaccines: Comparative evaluation of multicenter travel-clinic based experience",
            "volume": "19"
        },
        "b0080": {
            "authors": [
                {
                    "first": "David N.",
                    "initial": "D.N.",
                    "last": "Fisman"
                },
                {
                    "first": "Deepak",
                    "initial": "D.",
                    "last": "Agrawal"
                },
                {
                    "first": "Karin",
                    "initial": "K.",
                    "last": "Leder"
                }
            ],
            "doi": "10.1086/344271",
            "firstpage": "1368",
            "issn": "10584838",
            "lastpage": "1375",
            "pmid": "12439800",
            "pub_year": 2002,
            "title": "The effect of age on immunologic response to recombinant hepatitis B vaccine: A meta-analysis",
            "volume": "35"
        },
        "b0085": {
            "authors": [
                {
                    "first": "Bernd",
                    "initial": "B.",
                    "last": "Wolters"
                },
                {
                    "first": "Ulrich",
                    "initial": "U.",
                    "last": "Junge"
                },
                {
                    "first": "Stefan",
                    "initial": "S.",
                    "last": "Dziuba"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Roggendorf"
                }
            ],
            "doi": "10.1016/S0264-410X(03)00399-2",
            "firstpage": "3623",
            "issn": "0264410X",
            "lastpage": "3628",
            "pmid": "12922091",
            "pub_year": 2003,
            "title": "Immunogenicity of combined hepatitis A and B vaccine in elderly persons",
            "volume": "21"
        },
        "b0090": {
            "authors": [
                {
                    "first": "Marie",
                    "initial": "M.",
                    "last": "Van der Wielen"
                },
                {
                    "first": "Pierre",
                    "initial": "P.",
                    "last": "Van Damme"
                },
                {
                    "first": "Roman",
                    "initial": "R.",
                    "last": "Chlibek"
                },
                {
                    "first": "Jan",
                    "initial": "J.",
                    "last": "Smetana"
                },
                {
                    "first": "Frank",
                    "initial": "F.",
                    "last": "von Sonnenburg"
                }
            ],
            "doi": "10.1016/j.vaccine.2006.04.016",
            "firstpage": "5509",
            "issn": "0264410X",
            "lastpage": "5515",
            "pmid": "16725234",
            "pub_year": 2006,
            "title": "Hepatitis A/B vaccination of adults over 40 years old: Comparison of three vaccine regimens and effect of influencing factors",
            "volume": "24"
        },
        "b0095": null,
        "b0100": {
            "authors": [
                {
                    "first": "Meredith L.",
                    "initial": "M.L.",
                    "last": "Reilly"
                },
                {
                    "first": "Sarah F.",
                    "initial": "S.F.",
                    "last": "Schillie"
                },
                {
                    "first": "Emily",
                    "initial": "E.",
                    "last": "Smith"
                },
                {
                    "first": "Tasha",
                    "initial": "T.",
                    "last": "Poissant"
                },
                {
                    "first": "Candace W.",
                    "initial": "C.W.",
                    "last": "Vonderwahl"
                },
                {
                    "first": "Kristin",
                    "initial": "K.",
                    "last": "Gerard"
                },
                {
                    "first": "Jennifer",
                    "initial": "J.",
                    "last": "Baumgartner"
                },
                {
                    "first": "Lynne",
                    "initial": "L.",
                    "last": "Mercedes"
                },
                {
                    "first": "Kristin",
                    "initial": "K.",
                    "last": "Sweet"
                },
                {
                    "first": "Daniel",
                    "initial": "D.",
                    "last": "Muleta"
                },
                {
                    "first": "Daniel J.",
                    "initial": "D.J.",
                    "last": "Zaccaro"
                },
                {
                    "first": "Monina",
                    "initial": "M.",
                    "last": "Klevens"
                },
                {
                    "first": "Trudy V.",
                    "initial": "T.V.",
                    "last": "Murphy"
                }
            ],
            "doi": "10.1177/193229681200600417",
            "firstpage": "858",
            "issn": "19322968",
            "lastpage": "866",
            "pmid": "22920812",
            "pub_year": 2012,
            "title": "Increased risk of acute hepatitis B among adults with diagnosed diabetes mellitus",
            "volume": "6"
        },
        "b0105": {
            "authors": [
                {
                    "first": "Hashem B.",
                    "initial": "H.B.",
                    "last": "El-Serag"
                },
                {
                    "first": "Thomas",
                    "initial": "T.",
                    "last": "Tran"
                },
                {
                    "first": "James E.",
                    "initial": "J.E.",
                    "last": "Everhart"
                }
            ],
            "doi": "10.1053/j.gastro.2003.10.065",
            "firstpage": "460",
            "issn": "00165085",
            "lastpage": "468",
            "pmid": "14762783",
            "pub_year": 2004,
            "title": "Diabetes Increases the Risk of Chronic Liver Disease and Hepatocellular Carcinoma",
            "volume": "126"
        },
        "b0110": {
            "authors": [
                {
                    "first": "Mark H.",
                    "initial": "M.H.",
                    "last": "Sawyer"
                },
                {
                    "first": "Thomas J.",
                    "initial": "T.J.",
                    "last": "Hoerger"
                },
                {
                    "first": "Trudy V.",
                    "initial": "T.V.",
                    "last": "Murphy"
                },
                {
                    "first": "Sarah F.",
                    "initial": "S.F.",
                    "last": "Schillie"
                },
                {
                    "first": "Dale",
                    "initial": "D.",
                    "last": "Hu"
                },
                {
                    "first": "Philip R.",
                    "initial": "P.R.",
                    "last": "Spradling"
                },
                {
                    "first": "Kathy K.",
                    "initial": "K.K.",
                    "last": "Byrd"
                },
                {
                    "first": "Jian",
                    "initial": "J.",
                    "last": "Xing"
                },
                {
                    "first": "Meredith L.",
                    "initial": "M.L.",
                    "last": "Reilly"
                },
                {
                    "first": "Rania A.",
                    "initial": "R.A.",
                    "last": "Tohme"
                },
                {
                    "first": "Anne",
                    "initial": "A.",
                    "last": "Moorman"
                },
                {
                    "first": "Emily A.",
                    "initial": "E.A.",
                    "last": "Smith"
                },
                {
                    "first": "Brittney N.",
                    "initial": "B.N.",
                    "last": "Baack"
                },
                {
                    "first": "Ruth B.",
                    "initial": "R.B.",
                    "last": "Jiles"
                },
                {
                    "first": "Monina",
                    "initial": "M.",
                    "last": "Klevens"
                },
                {
                    "first": "John W.",
                    "initial": "J.W.",
                    "last": "Ward"
                },
                {
                    "first": "Henry S.",
                    "initial": "H.S.",
                    "last": "Kahn"
                },
                {
                    "first": "Fangjun",
                    "initial": "F.",
                    "last": "Zhou"
                }
            ],
            "firstpage": "1709",
            "issn": "01492195",
            "lastpage": "1711",
            "pmid": "22189894",
            "pub_year": 2011,
            "title": "Use of hepatitis B vaccination for adults with diabetes mellitus: Recommendations of the advisory committee on immunization practices (ACIP)",
            "volume": "60"
        },
        "b0115": {
            "authors": [
                {
                    "first": "Matthew J.",
                    "initial": "M.J.",
                    "last": "Alcusky"
                },
                {
                    "first": "Jayne",
                    "initial": "J.",
                    "last": "Pawasauskas"
                }
            ],
            "doi": "10.2337/diaclin.33.3.116",
            "firstpage": "116",
            "issn": "08918929",
            "lastpage": "122",
            "pub_year": 2015,
            "title": "Adherence to guidelines for hepatitis B, pneumococcal, and influenza vaccination in patients with diabetes",
            "volume": "33"
        },
        "b0120": {
            "authors": [
                {
                    "first": "Walter W.",
                    "initial": "W.W.",
                    "last": "Williams"
                },
                {
                    "first": "Peng Jun",
                    "initial": "P.J.",
                    "last": "Lu"
                },
                {
                    "first": "Alissa",
                    "initial": "A.",
                    "last": "O'Halloran"
                },
                {
                    "first": "David K.",
                    "initial": "D.K.",
                    "last": "Kim"
                },
                {
                    "first": "Lisa A.",
                    "initial": "L.A.",
                    "last": "Grohskopf"
                },
                {
                    "first": "Tamara",
                    "initial": "T.",
                    "last": "Pilishvili"
                },
                {
                    "first": "Tami H.",
                    "initial": "T.H.",
                    "last": "Skoff"
                },
                {
                    "first": "Noele P.",
                    "initial": "N.P.",
                    "last": "Nelson"
                },
                {
                    "first": "Rafael",
                    "initial": "R.",
                    "last": "Harpaz"
                },
                {
                    "first": "Lauri E.",
                    "initial": "L.E.",
                    "last": "Markowitz"
                },
                {
                    "first": "Alfonso",
                    "initial": "A.",
                    "last": "Rodriguez-Lainz"
                },
                {
                    "first": "Amy Parker",
                    "initial": "A.P.",
                    "last": "Fiebelkorn"
                }
            ],
            "doi": "10.15585/mmwr.ss6611a1",
            "firstpage": "1",
            "issn": "15460738",
            "lastpage": "28",
            "pmid": "28472027",
            "pub_year": 2017,
            "title": "Surveillance of vaccination coverage among adult populations-United States, 2015",
            "volume": "66"
        },
        "b0125": {
            "authors": [
                {
                    "first": "Veit",
                    "initial": "V.",
                    "last": "Hornung"
                },
                {
                    "first": "Simon",
                    "initial": "S.",
                    "last": "Rothenfusser"
                },
                {
                    "first": "Stefanie",
                    "initial": "S.",
                    "last": "Britsch"
                },
                {
                    "first": "Anne",
                    "initial": "A.",
                    "last": "Krug"
                },
                {
                    "first": "Bernd",
                    "initial": "B.",
                    "last": "Jahrsd\u00f6rfer"
                },
                {
                    "first": "Thomas",
                    "initial": "T.",
                    "last": "Giese"
                },
                {
                    "first": "Stefan",
                    "initial": "S.",
                    "last": "Endres"
                },
                {
                    "first": "Gunther",
                    "initial": "G.",
                    "last": "Hartmann"
                }
            ],
            "doi": "10.4049/jimmunol.168.9.4531",
            "firstpage": "4531",
            "issn": "00221767",
            "lastpage": "4537",
            "pmid": "11970999",
            "pub_year": 2002,
            "title": "Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides",
            "volume": "168"
        },
        "b0130": {
            "authors": [
                {
                    "first": "Ennio",
                    "initial": "E.",
                    "last": "De Gregorio"
                },
                {
                    "first": "Elena",
                    "initial": "E.",
                    "last": "Caproni"
                },
                {
                    "first": "Jeffrey B.",
                    "initial": "J.B.",
                    "last": "Ulmer"
                }
            ],
            "doi": "10.3389/fimmu.2013.00214",
            "issn": "16643224",
            "pub_year": 2013,
            "title": "Vaccine adjuvants: Mode of action",
            "volume": "4"
        },
        "b0135": {
            "authors": [
                {
                    "first": "Scott A.",
                    "initial": "S.A.",
                    "last": "Halperin"
                },
                {
                    "first": "Brian",
                    "initial": "B.",
                    "last": "Ward"
                },
                {
                    "first": "Curtis",
                    "initial": "C.",
                    "last": "Cooper"
                },
                {
                    "first": "Gerald",
                    "initial": "G.",
                    "last": "Predy"
                },
                {
                    "first": "Francisco",
                    "initial": "F.",
                    "last": "Diaz-Mitoma"
                },
                {
                    "first": "Marc",
                    "initial": "M.",
                    "last": "Dionne"
                },
                {
                    "first": "Joanne",
                    "initial": "J.",
                    "last": "Embree"
                },
                {
                    "first": "Allison",
                    "initial": "A.",
                    "last": "McGeer"
                },
                {
                    "first": "Paul",
                    "initial": "P.",
                    "last": "Zickler"
                },
                {
                    "first": "Karl Heinz",
                    "initial": "K.H.",
                    "last": "Moltz"
                },
                {
                    "first": "Ren\u00e9",
                    "initial": "R.",
                    "last": "Martz"
                },
                {
                    "first": "Ingo",
                    "initial": "I.",
                    "last": "Meyer"
                },
                {
                    "first": "Shelly",
                    "initial": "S.",
                    "last": "McNeil"
                },
                {
                    "first": "Joanne M.",
                    "initial": "J.M.",
                    "last": "Langley"
                },
                {
                    "first": "Eduardo",
                    "initial": "E.",
                    "last": "Martins"
                },
                {
                    "first": "William L.",
                    "initial": "W.L.",
                    "last": "Heyward"
                },
                {
                    "first": "J. Tyler",
                    "initial": "J.T.",
                    "last": "Martin"
                }
            ],
            "doi": "10.1016/j.vaccine.2012.01.087",
            "firstpage": "2556",
            "issn": "0264410X",
            "lastpage": "2563",
            "pmid": "22326642",
            "pub_year": 2012,
            "title": "Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18-55 years of age",
            "volume": "30"
        },
        "b0140": {
            "authors": [
                {
                    "first": "William L.",
                    "initial": "W.L.",
                    "last": "Heyward"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Kyle"
                },
                {
                    "first": "Joseph",
                    "initial": "J.",
                    "last": "Blumenau"
                },
                {
                    "first": "Matthew",
                    "initial": "M.",
                    "last": "Davis"
                },
                {
                    "first": "Keith",
                    "initial": "K.",
                    "last": "Reisinger"
                },
                {
                    "first": "Martin L.",
                    "initial": "M.L.",
                    "last": "Kabongo"
                },
                {
                    "first": "Sean",
                    "initial": "S.",
                    "last": "Bennett"
                },
                {
                    "first": "Robert S.",
                    "initial": "R.S.",
                    "last": "Janssen"
                },
                {
                    "first": "Hamid",
                    "initial": "H.",
                    "last": "Namini"
                },
                {
                    "first": "J. Tyler",
                    "initial": "J.T.",
                    "last": "Martin"
                }
            ],
            "doi": "10.1016/j.vaccine.2013.05.068",
            "firstpage": "5300",
            "issn": "0264410X",
            "lastpage": "5305",
            "pmid": "23727002",
            "pub_year": 2013,
            "title": "Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40-70 years of age",
            "volume": "31"
        },
        "b0145": null,
        "b0150": {
            "authors": [
                {
                    "first": "Olli",
                    "initial": "O.",
                    "last": "Miettinen"
                },
                {
                    "first": "Markku",
                    "initial": "M.",
                    "last": "Nurminen"
                }
            ],
            "doi": "10.1002/sim.4780040211",
            "firstpage": "213",
            "issn": "02776715",
            "lastpage": "226",
            "pmid": "4023479",
            "pub_year": 1985,
            "title": "Comparative analysis of two rates",
            "volume": "4"
        },
        "b0155": null,
        "b0160": null,
        "b0165": {
            "authors": [
                {
                    "first": "Gillian J.",
                    "initial": "G.J.",
                    "last": "Buckley"
                },
                {
                    "first": "Brian L.",
                    "initial": "B.L.",
                    "last": "Strom"
                }
            ],
            "doi": "10.17226/24731",
            "firstpage": "1",
            "lastpage": "280",
            "pub_year": 2017,
            "title": "A National Strategy for the Elimination of Hepatitis B and C"
        },
        "b0170": {
            "authors": [
                {
                    "first": "Sarah F.",
                    "initial": "S.F.",
                    "last": "Schillie"
                },
                {
                    "first": "Philip R.",
                    "initial": "P.R.",
                    "last": "Spradling"
                },
                {
                    "first": "Trudy V.",
                    "initial": "T.V.",
                    "last": "Murphy"
                }
            ],
            "doi": "10.2337/dc12-0312",
            "firstpage": "2690",
            "issn": "01495992",
            "lastpage": "2697",
            "pmid": "23173138",
            "pub_year": 2012,
            "title": "Immune response of hepatitis B vaccine among persons with diabetes: A systematic review of the literature",
            "volume": "35"
        },
        "b0175": null,
        "b0180": null,
        "b0185": {
            "authors": [
                {
                    "first": "Julia M.",
                    "initial": "J.M.",
                    "last": "Janssen"
                },
                {
                    "first": "Sam",
                    "initial": "S.",
                    "last": "Jackson"
                },
                {
                    "first": "William L.",
                    "initial": "W.L.",
                    "last": "Heyward"
                },
                {
                    "first": "Robert S.",
                    "initial": "R.S.",
                    "last": "Janssen"
                }
            ],
            "doi": "10.1016/j.vaccine.2015.05.070",
            "firstpage": "3614",
            "issn": "0264410X",
            "lastpage": "3618",
            "pmid": "26067185",
            "pub_year": 2015,
            "title": "Immunogenicity of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in subpopulations of healthy adults 18-70 years of age",
            "volume": "33"
        },
        "b0190": {
            "authors": [
                {
                    "first": "Jennifer C.",
                    "initial": "J.C.",
                    "last": "Nelson"
                },
                {
                    "first": "Rachel C.L.",
                    "initial": "R.C.L.",
                    "last": "Bittner"
                },
                {
                    "first": "Lora",
                    "initial": "L.",
                    "last": "Bounds"
                },
                {
                    "first": "Shanshan",
                    "initial": "S.",
                    "last": "Zhao"
                },
                {
                    "first": "James",
                    "initial": "J.",
                    "last": "Baggs"
                },
                {
                    "first": "James G.",
                    "initial": "J.G.",
                    "last": "Donahue"
                },
                {
                    "first": "Simon J.",
                    "initial": "S.J.",
                    "last": "Hambidge"
                },
                {
                    "first": "Steven J.",
                    "initial": "S.J.",
                    "last": "Jacobsen"
                },
                {
                    "first": "Nicola P.",
                    "initial": "N.P.",
                    "last": "Klein"
                },
                {
                    "first": "Allison L.",
                    "initial": "A.L.",
                    "last": "Naleway"
                },
                {
                    "first": "Kenneth M.",
                    "initial": "K.M.",
                    "last": "Zangwill"
                },
                {
                    "first": "Lisa A.",
                    "initial": "L.A.",
                    "last": "Jackson"
                }
            ],
            "doi": "10.2105/AJPH.2008.151332",
            "firstpage": "S389",
            "issn": "00900036",
            "lastpage": "S397",
            "pmid": "19797753",
            "pub_year": 2009,
            "title": "Compliance with multiple-dose vaccine schedules among older children, adolescents, and adults: Results from a vaccine safety datalink study",
            "volume": "99"
        },
        "b0195": {
            "authors": [
                {
                    "first": "Robert A.",
                    "initial": "R.A.",
                    "last": "Gunn"
                },
                {
                    "first": "Marjorie A.",
                    "initial": "M.A.",
                    "last": "Lee"
                },
                {
                    "first": "Paula J.",
                    "initial": "P.J.",
                    "last": "Murray"
                },
                {
                    "first": "Robert A.",
                    "initial": "R.A.",
                    "last": "Gilchick"
                },
                {
                    "first": "Harold S.",
                    "initial": "H.S.",
                    "last": "Margolis"
                }
            ],
            "doi": "10.1097/01.olq.0000258306.20287.a7",
            "firstpage": "663",
            "issn": "01485717",
            "lastpage": "668",
            "pmid": "17847164",
            "pub_year": 2007,
            "title": "Hepatitis B vaccination of men who have sex with men attending an urban STD clinic: Impact of an ongoing vaccination program, 1998-2003",
            "volume": "34"
        },
        "b0200": {
            "authors": [
                {
                    "first": "Maria Elena",
                    "initial": "M.E.",
                    "last": "Tosti"
                },
                {
                    "first": "Valeria",
                    "initial": "V.",
                    "last": "Alfonsi"
                },
                {
                    "first": "Eleonora",
                    "initial": "E.",
                    "last": "Lacorte"
                },
                {
                    "first": "Alfonso",
                    "initial": "A.",
                    "last": "Mele"
                },
                {
                    "first": "Cristina",
                    "initial": "C.",
                    "last": "Galli"
                },
                {
                    "first": "Alessandro Remo",
                    "initial": "A.R.",
                    "last": "Zanetti"
                },
                {
                    "first": "Luisa",
                    "initial": "L.",
                    "last": "Roman\u00f2"
                }
            ],
            "doi": "10.1093/cid/ciw162",
            "firstpage": "1412",
            "issn": "10584838",
            "lastpage": "1418",
            "pmid": "27009250",
            "pub_year": 2016,
            "title": "Acute Hepatitis B after the implementation of universal vaccination in Italy: Results from 22 years of surveillance (1993-2014)",
            "volume": "62"
        }
    },
    "body_text": [
        {
            "endOffset": 29527,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "For the primary immunogenicity endpoint in participants with type 2 diabetes mellitus, the per-protocol population comprised all randomized participants who received all study injections, had no major protocol deviations that could affect immunogenicity, and had anti-HBs levels obtained within the protocol-defined study visit window at week 28.",
            "startOffset": 29181,
            "title": "Statistical methods"
        },
        {
            "endOffset": 21551,
            "parents": [],
            "refoffsets": {
                "b0110": {
                    "endOffset": 21550,
                    "startOffset": 21546
                }
            },
            "secId": "s0005",
            "sentence": "In 2011, CDC\u2019s Advisory Committee on Immunization Practices recommended that in the US, hepatitis B vaccination be routinely administered to all unvaccinated adults with diabetes <60 years of age and to unvaccinated adults with diabetes who are \u226560 years of age at the discretion of the treating clinician [22].",
            "startOffset": 21240,
            "title": "Introduction"
        },
        {
            "endOffset": 37835,
            "parents": [],
            "secId": "s0065",
            "sentence": "A limitation of this study is that persons who had previously received hepatitis B vaccine and had an anti-HBs level <10 mIU/mL may have been enrolled.",
            "startOffset": 37684,
            "title": "Discussion"
        },
        {
            "endOffset": 21877,
            "parents": [],
            "secId": "s0005",
            "sentence": "HBsAg-1018 (HEPLISAV-B\u2122) is a hepatitis B vaccine developed by Dynavax Technologies Corporation (Berkeley, CA) that utilizes a cytidine-phosphate-guanosine oligodeoxynucleotide (CpG-ODN), 1018, as an adjuvant.",
            "startOffset": 21668,
            "title": "Introduction"
        },
        {
            "endOffset": 22874,
            "parents": [],
            "secId": "s0005",
            "sentence": "In this trial of 8374 adults, the immunogenicity and safety of HBsAg-1018 were compared to the most commonly used licensed hepatitis B vaccine, HBsAg-Eng, in populations known to have good responses (young adults, women, persons without diabetes, non-obese, and non-smokers) and in populations known to have reduced rates of seroprotection (eg, older adults, men, persons with diabetes, the obese, and smokers).",
            "startOffset": 22463,
            "title": "Introduction"
        },
        {
            "endOffset": 26304,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Saline placebo was administered as the third injection at week 24 to maintain blinding.",
            "startOffset": 26217,
            "title": "Study vaccines and administration"
        },
        {
            "endOffset": 24866,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Key secondary objectives were to demonstrate noninferiority of the SPR at week 24 induced by HBsAg-1018 to the SPR at week 28 induced by HBsAg-Eng in the total study population and in the following subgroups: by age, sex, body mass index (BMI), and smoking status, and if noninferiority was established, to demonstrate that the SPR induced by HBsAg-1018 was statistically significantly higher than that induced by HBsAg-Eng.",
            "startOffset": 24442,
            "title": "Key trial objectives"
        },
        {
            "endOffset": 36938,
            "parents": [],
            "secId": "s0065",
            "sentence": "Because of active follow up in a phase 3 clinical trial, adherence to a two-dose vaccine regimen cannot be compared with a three-dose vaccine regimen.",
            "startOffset": 36788,
            "title": "Discussion"
        },
        {
            "endOffset": 26491,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "HBsAg-Eng (Engerix-B, GlaxoSmithKline Biologicals, Rixensart, Belgium) consists of 20 mcg of recombinant HBsAg combined with 500 mcg of aluminum hydroxide (alum) adjuvant per 1.0 mL dose.",
            "startOffset": 26304,
            "title": "Study vaccines and administration"
        },
        {
            "endOffset": 33062,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "In the reverse cumulative frequency plot of anti-HBs concentrations (Fig. 3), the HBsAg-1018 curve has a fairly steep slope indicating a relative narrow distribution of antibody responses.",
            "startOffset": 32874,
            "title": "Exploratory analyses"
        },
        {
            "endOffset": 26216,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "HBsAg-1018 (HEPLISAV-B manufactured for Dynavax Technologies Corporation, Berkeley, California by Rentschler Biotechnologie GmbH, Laupheim, Germany) consists of 20 mcg of yeast-derived recombinant HBsAg (subtype adw) and 3000 mcg of 1018 adjuvant per 0.5 mL dose and was administered by intramuscular injection in the deltoid muscle at weeks 0 and 4.",
            "startOffset": 25866,
            "title": "Study vaccines and administration"
        },
        {
            "endOffset": 31430,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "In the exploratory sensitivity analysis, treatment group, age, BMI, and duration of diabetes significantly affected the SPR (p < .05).",
            "startOffset": 31296,
            "title": "Primary analysis"
        },
        {
            "endOffset": 33731,
            "parents": [],
            "secId": "s0065",
            "sentence": "Vaccinating adults at risk for hepatitis B remains a challenge.",
            "startOffset": 33668,
            "title": "Discussion"
        },
        {
            "endOffset": 32874,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "In the total per-protocol population, at week 24, the GMC in the HBsAg-1018 group (401.0 mIU/mL) was significantly higher than the GMC at week 28 in the HBsAg-Eng group (324.0 mIU/mL) (ratio of GMCs = 1.2; 95% CI: 1.1, 1.4).",
            "startOffset": 32650,
            "title": "Exploratory analyses"
        },
        {
            "endOffset": 30252,
            "parents": [],
            "secId": "s0040",
            "sentence": "A total of 7659 (91.5%) participants completed the study (Fig. 1) with a similar percentage in each vaccine group.",
            "startOffset": 30138,
            "title": "Results"
        },
        {
            "endOffset": 30682,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0045",
            "sentence": "Demographic and baseline characteristics known to affect immunogenicity, including age, sex, diabetes mellitus, BMI, and smoking were similar across vaccine groups (Table 1).",
            "startOffset": 30508,
            "title": "Demographic and baseline characteristics"
        },
        {
            "endOffset": 38591,
            "parents": [],
            "secId": "s0065",
            "sentence": "The significantly higher SPRs induced by HBsAg-1018 and the similar safety profile suggest that HBsAg-1018 can overcome limitations of the alum-adjuvanted, licensed hepatitis B vaccines.",
            "startOffset": 38405,
            "title": "Discussion"
        },
        {
            "endOffset": 34838,
            "parents": [],
            "refoffsets": {
                "b0170": {
                    "endOffset": 34837,
                    "startOffset": 34833
                }
            },
            "secId": "s0065",
            "sentence": "Others have reported that diabetes control and severity of diabetes were not associated with seroprotection [34].",
            "startOffset": 34725,
            "title": "Discussion"
        },
        {
            "endOffset": 27401,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Anti-HBs serum concentrations were measured at screening and at 24 and 28 weeks using the Ortho Vitros\u00ae enhanced chemiluminescence immunoassay (Ortho Vitros\u00ae Version 2.1, Rochester, NY).",
            "startOffset": 27215,
            "title": "Serological assessments"
        },
        {
            "endOffset": 33523,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "While a significantly higher proportion of participants who received HBsAg-1018 developed a seroprotective antibody level compared with participants who received HBsAg-Eng, a significantly lower proportion of participants who received HBsAg-1018 (1.5%) had anti-HBs levels \u2265 10,000 mIU/mL than those who received HBsAg-Eng (13.8%).",
            "startOffset": 33192,
            "title": "Exploratory analyses"
        },
        {
            "endOffset": 28765,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "refoffsets": {
                "b0150": {
                    "endOffset": 28764,
                    "startOffset": 28760
                }
            },
            "secId": "s0035",
            "sentence": "The 95% CI of the difference in SPRs between the vaccine groups used the Miettinen and Nurminen method without stratification [30].",
            "startOffset": 28634,
            "title": "Statistical methods"
        },
        {
            "endOffset": 38124,
            "parents": [],
            "secId": "s0065",
            "sentence": "Adherence in this study is unlikely to represent adherence outside the clinical trial setting because participants were actively followed and were remunerated for their participation.",
            "startOffset": 37941,
            "title": "Discussion"
        },
        {
            "endOffset": 32187,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "The results of the analysis of the total study mITT population were similar to the per-protocol population.",
            "startOffset": 32080,
            "title": "Secondary analyses"
        },
        {
            "endOffset": 36101,
            "parents": [],
            "refoffsets": {
                "b0185": {
                    "endOffset": 36100,
                    "startOffset": 36096
                }
            },
            "secId": "s0065",
            "sentence": "These immunogenicity results were consistent with exploratory analyses in the two previous phase 3 trials [37].",
            "startOffset": 35990,
            "title": "Discussion"
        },
        {
            "endOffset": 36395,
            "parents": [],
            "secId": "s0065",
            "sentence": "The greater immunogenicity of HBsAg-1018 was likely not due to the induction of higher overall antibody levels across the vaccinated population rather it is the result of a much more uniform and efficient induction of protective antibody levels across a broad spectrum of recipient populations.",
            "startOffset": 36101,
            "title": "Discussion"
        },
        {
            "endOffset": 38939,
            "parents": [],
            "secId": "s0065",
            "sentence": "By virtue of HBsAg-1018\u2019s improved immunogenicity and one month dosing regimen, HBsAg-1018 can make an important public health contribution by reducing the number of hepatitis B infections and associated morbidity and mortality in adults.",
            "startOffset": 38701,
            "title": "Discussion"
        },
        {
            "endOffset": 22210,
            "parents": [],
            "refoffsets": {
                "b0130": {
                    "endOffset": 22209,
                    "startOffset": 22205
                }
            },
            "secId": "s0005",
            "sentence": "1018 stimulates a directed immune response to hepatitis B surface antigen (HBsAg) instead of the multi-pathway, broad immunostimulatory response induced by alum [26].",
            "startOffset": 22044,
            "title": "Introduction"
        },
        {
            "endOffset": 22345,
            "parents": [],
            "refoffsets": {
                "b0135": {
                    "endOffset": 22344,
                    "startOffset": 22337
                },
                "b0140": {
                    "endOffset": 22344,
                    "startOffset": 22337
                }
            },
            "secId": "s0005",
            "sentence": "HBsAg-1018 has induced significantly higher and earlier seroprotection rates in healthy adults in two previous phase 3 trials [27,28].",
            "startOffset": 22211,
            "title": "Introduction"
        },
        {
            "endOffset": 28468,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "The total sample size of 8250 was based on a primary objective to assess safety in approximately 5000 HBsAg-1018 participants through week 56 as requested by regulatory authorities.",
            "startOffset": 28287,
            "title": "Statistical methods"
        },
        {
            "endOffset": 29677,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "The modified intent-to-treat (mITT) population included all participants who received at least one injection and at least one anti-HBs determination.",
            "startOffset": 29528,
            "title": "Statistical methods"
        },
        {
            "endOffset": 37286,
            "parents": [],
            "refoffsets": {
                "b0190": {
                    "endOffset": 37285,
                    "startOffset": 37281
                }
            },
            "secId": "s0065",
            "sentence": "In a Vaccine Safety Datalink study of more than 88,000 adult hepatitis B vaccine recipients, 81% received at least two doses and only 54% received all three doses within one year [38].",
            "startOffset": 37102,
            "title": "Discussion"
        },
        {
            "endOffset": 31296,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "The difference between SPRs met the prospectively defined criteria for the primary endpoint of noninferiority as well as the secondary endpoint being statistically significantly higher.",
            "startOffset": 31111,
            "title": "Primary analysis"
        },
        {
            "endOffset": 23456,
            "parents": [],
            "secId": "s0010",
            "sentence": "Safety will be reported in another paper.",
            "startOffset": 23415,
            "title": "Materials and methods"
        },
        {
            "endOffset": 20933,
            "parents": [],
            "refoffsets": {
                "b0040": {
                    "endOffset": 20748,
                    "startOffset": 20742
                },
                "b0045": {
                    "endOffset": 20748,
                    "startOffset": 20742
                },
                "b0050": {
                    "endOffset": 20748,
                    "startOffset": 20742
                },
                "b0055": {
                    "endOffset": 20748,
                    "startOffset": 20742
                },
                "b0060": {
                    "endOffset": 20748,
                    "startOffset": 20742
                },
                "b0065": {
                    "endOffset": 20748,
                    "startOffset": 20742
                },
                "b0070": {
                    "endOffset": 20748,
                    "startOffset": 20742
                },
                "b0075": {
                    "endOffset": 20748,
                    "startOffset": 20742
                },
                "b0080": {
                    "endOffset": 20748,
                    "startOffset": 20742
                },
                "b0085": {
                    "endOffset": 20748,
                    "startOffset": 20742
                },
                "b0090": {
                    "endOffset": 20748,
                    "startOffset": 20742
                },
                "b0095": {
                    "endOffset": 20913,
                    "startOffset": 20909
                }
            },
            "secId": "s0005",
            "sentence": "The currently approved vaccines: (1) have reduced immunologic responses in older adults, men, individuals with diabetes mellitus, obese individuals, and smokers [8\u201318]; (2) require adherence to a 3-dose vaccination schedule over 6 months [19]; and, (3) have a prolonged time before development of seroprotection (ie, >6 months) [19] in many recipients.",
            "startOffset": 20581,
            "title": "Introduction"
        },
        {
            "endOffset": 38700,
            "parents": [],
            "refoffsets": {
                "b0190": {
                    "endOffset": 38699,
                    "startOffset": 38692
                },
                "b0195": {
                    "endOffset": 38699,
                    "startOffset": 38692
                }
            },
            "secId": "s0065",
            "sentence": "Importantly, HBsAg-1018 also has the potential to be an improvement over current rates of adherence [38,39].",
            "startOffset": 38592,
            "title": "Discussion"
        },
        {
            "endOffset": 28287,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "An exploratory sensitivity analysis for the primary endpoint SPR used a stepwise logistic regression to examine treatment group, age, sex, race, BMI, smoking history, duration of diabetes (<5 years vs \u2265 5 years), baseline hemoglobin A1c (HbA1c) level (<6.5%, 6.5\u20139.0%, and >9.0%), number of diabetes complications, metformin use, and immunosuppressive medication use.",
            "startOffset": 27920,
            "title": "Statistical methods"
        },
        {
            "endOffset": 34524,
            "parents": [],
            "secId": "s0065",
            "sentence": "In this trial, two doses of HBsAg-1018 over one month induced a significantly higher SPR (90.0%) in participants with diabetes mellitus than three doses of HBsAg-Eng over 6 months (65.1%).",
            "startOffset": 34336,
            "title": "Discussion"
        },
        {
            "endOffset": 36788,
            "parents": [],
            "secId": "s0065",
            "sentence": "In addition, the range of SPRs in the HBsAg-Eng populations was threefold greater than across the HBsAg-1018 populations.",
            "startOffset": 36667,
            "title": "Discussion"
        },
        {
            "endOffset": 28933,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "For the primary objective, HBsAg-1018 was considered noninferior to HBsAg-Eng if the lower limit of the 2-sided 95% CI of the difference in SPRs was greater than \u221210%.",
            "startOffset": 28766,
            "title": "Statistical methods"
        },
        {
            "endOffset": 20580,
            "parents": [],
            "refoffsets": {
                "b0030": {
                    "endOffset": 20483,
                    "startOffset": 20478
                },
                "b0035": {
                    "endOffset": 20483,
                    "startOffset": 20478
                }
            },
            "secId": "s0005",
            "sentence": "Ongoing HBV infections in adults can be attributed to the challenges of vaccinating adults at risk of infection [6,7] and the limitations of the currently approved vaccines (Engerix-B\u00ae [HBsAg-Eng] and Recombivax\u00ae).",
            "startOffset": 20366,
            "title": "Introduction"
        },
        {
            "endOffset": 23702,
            "parents": [],
            "secId": "s0010",
            "sentence": "A central institutional review board approved the protocol and the trial was conducted according to the Declaration of Helsinki and Good Clinical Practices.",
            "startOffset": 23546,
            "title": "Materials and methods"
        },
        {
            "endOffset": 37940,
            "parents": [],
            "secId": "s0065",
            "sentence": "However, it is likely that such persons would have been randomized 2:1 consistent with the total cohort.",
            "startOffset": 37836,
            "title": "Discussion"
        },
        {
            "endOffset": 27215,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "After completing screening and the initial injection at week 0, participants returned to the clinic site at weeks 4, 24, 28, and 56 to undergo safety evaluations and to have blood drawn for anti-HBs serum concentrations at week 24 and 28.",
            "startOffset": 26977,
            "title": "Serological assessments"
        },
        {
            "endOffset": 19525,
            "parents": [],
            "secId": "s0005",
            "sentence": "Hepatitis B virus (HBV) infection is a major public health problem globally including the United States (US).",
            "startOffset": 19416,
            "title": "Introduction"
        },
        {
            "endOffset": 29775,
            "parents": [],
            "secId": "s0040",
            "sentence": "A total of 8374 participants were randomized including 1144 with type 2 diabetes mellitus.",
            "startOffset": 29685,
            "title": "Results"
        },
        {
            "endOffset": 30465,
            "parents": [],
            "secId": "s0040",
            "sentence": "There were 6826 participants in the per-protocol population, representing 81.5% of the randomized population, and including 961 participants with type 2 diabetes mellitus (HBsAg-1018: n = 640; HBsAg-Eng: n = 321).",
            "startOffset": 30252,
            "title": "Results"
        },
        {
            "endOffset": 39280,
            "parents": [],
            "secId": "s0075",
            "sentence": "Dynavax Technologies Corporation designed, funded, and provided oversight for this study.",
            "startOffset": 39191,
            "title": "Role of the funding source"
        },
        {
            "endOffset": 38282,
            "parents": [],
            "secId": "s0065",
            "sentence": "Thus, seroprotection rates are likely to be lower outside the clinical trial setting, particularly for a vaccine administered in three doses over six months.",
            "startOffset": 38125,
            "title": "Discussion"
        },
        {
            "endOffset": 34978,
            "parents": [],
            "secId": "s0065",
            "sentence": "However, this is the first report that longer duration of type 2 diabetes may be associated with a reduced response to hepatitis B vaccine.",
            "startOffset": 34839,
            "title": "Discussion"
        },
        {
            "endOffset": 26872,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Randomization was stratified by site, age group (18 to 39, 40 to 70 years), and type 2 diabetes mellitus status and performed centrally using an electronic interactive response system.",
            "startOffset": 26688,
            "title": "Study vaccines and administration"
        },
        {
            "endOffset": 21668,
            "parents": [],
            "refoffsets": {
                "b0115": {
                    "endOffset": 21667,
                    "startOffset": 21660
                },
                "b0120": {
                    "endOffset": 21667,
                    "startOffset": 21660
                }
            },
            "secId": "s0005",
            "sentence": "Since the recommendations were released, little progress has been made in vaccinating persons with diabetes [23,24].",
            "startOffset": 21552,
            "title": "Introduction"
        },
        {
            "endOffset": 30138,
            "parents": [],
            "secId": "s0040",
            "sentence": "The most common reasons for screen failure were seropositivity for anti-HBs (64.8%), any medical condition considered by the investigator likely to interfere with study compliance or interpretation of study assessments (11.4%), not able to follow all required study procedures and attend scheduled visits (9.3%), and a known history of autoimmune disease (7.5%).",
            "startOffset": 29776,
            "title": "Results"
        },
        {
            "endOffset": 31110,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "The SPR at the primary endpoint among participants with type 2 diabetes mellitus in the HBsAg-1018 group was 90.0% (576/640) and the SPR in the HBsAg-Eng group was 65.1% (209/321) with a difference of 24.9% (95% CI: 19.3%, 30.7%) (Fig. 2).",
            "startOffset": 30871,
            "title": "Primary analysis"
        },
        {
            "endOffset": 23227,
            "parents": [],
            "secId": "s0005",
            "sentence": "Secondary endpoints were seroprotection rates in the total study population and by factors associated with reduced seroprotection rates from the alum adjuvanted vaccines.",
            "startOffset": 23057,
            "title": "Introduction"
        },
        {
            "endOffset": 26687,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Participants were randomly assigned 2:1 to receive HBsAg-1018 or HBsAg-Eng.",
            "startOffset": 26612,
            "title": "Study vaccines and administration"
        },
        {
            "endOffset": 24441,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Diabetes mellitus was defined as having a clinical diagnosis of type 2 diabetes mellitus and taking at least an oral or non-insulin injectable hypoglycemic agent and/or insulin.",
            "startOffset": 24264,
            "title": "Key trial objectives"
        },
        {
            "endOffset": 32650,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "In the per-protocol population, the geometric mean concentration (GMC) at week 24 in participants with diabetes mellitus in the HBsAg-1018 group (193.1 mIU/mL) was significantly higher than the GMC at week 28 in the HBsAg-Eng group (75.9 mIU/mL) (ratio of GMCs = 2.5; 95% CI: 1.8, 3.5).",
            "startOffset": 32364,
            "title": "Exploratory analyses"
        },
        {
            "endOffset": 20166,
            "parents": [],
            "refoffsets": {
                "b0020": {
                    "endOffset": 20165,
                    "startOffset": 20162
                }
            },
            "secId": "s0005",
            "sentence": "Despite the availability of vaccines for HBV, rates of acute hepatitis B infection have recently increased in the US [4].",
            "startOffset": 20045,
            "title": "Introduction"
        },
        {
            "endOffset": 21239,
            "parents": [],
            "refoffsets": {
                "b0100": {
                    "endOffset": 21238,
                    "startOffset": 21231
                },
                "b0105": {
                    "endOffset": 21238,
                    "startOffset": 21231
                },
                "b0110": {
                    "endOffset": 21238,
                    "startOffset": 21231
                }
            },
            "secId": "s0005",
            "sentence": "In the US, individuals with diabetes mellitus have approximately twice the risk of HBV infection and those who contract HBV have higher rates of complications including acute symptomatic hepatitis, chronic HBV infection, hepatocellular carcinoma, and death compared to individuals without diabetes [20\u201322].",
            "startOffset": 20933,
            "title": "Introduction"
        },
        {
            "endOffset": 31909,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "In participants with diabetes in the mITT population, the difference between SPRs at the primary endpoint between the HBsAg-1018 group (89.4%) and the HBsAg-Eng group (65.2%; difference in SPRs = 24.2%; 95% CI: 18.9%, 29.6%) was similar to that observed in the per-protocol population.",
            "startOffset": 31624,
            "title": "Primary analysis"
        },
        {
            "endOffset": 27629,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "The sample size calculation for the primary immunogenicity endpoint of SPR at week 28 in participants with diabetes mellitus was designed to demonstrate noninferiority with a one-sided alpha level of 0.025.",
            "startOffset": 27423,
            "title": "Statistical methods"
        },
        {
            "endOffset": 39068,
            "parents": [],
            "secId": "s0070",
            "sentence": "Sam Jackson, Robert Janssen, and Kimberly Erby were Dynavax employees when the trial was conducted.",
            "startOffset": 38969,
            "title": "Conflict of interest statement"
        },
        {
            "endOffset": 33191,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "The HBsAg-Eng curve has a relatively shallow slope indicating a greater variability in the antibody response than to HBsAg-1018.",
            "startOffset": 33063,
            "title": "Exploratory analyses"
        },
        {
            "endOffset": 26951,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Participants were followed for 56 weeks following their first dose of vaccine.",
            "startOffset": 26873,
            "title": "Study vaccines and administration"
        },
        {
            "endOffset": 25360,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Eligible participants were adults 18 through 70 years of age who were seronegative for HBsAg, anti-HBs, antibody against hepatitis B core antigen (anti-HBc), and human immunodeficiency virus.",
            "startOffset": 25169,
            "title": "Study population"
        },
        {
            "endOffset": 22043,
            "parents": [],
            "refoffsets": {
                "b0125": {
                    "endOffset": 22042,
                    "startOffset": 22038
                }
            },
            "secId": "s0005",
            "sentence": "CpG-ODNs bind Toll-like receptor 9 (TLR9), an innate immune system pattern recognition receptor for DNA expressed predominantly in plasmacytoid dendritic cells [25].",
            "startOffset": 21878,
            "title": "Introduction"
        },
        {
            "endOffset": 20366,
            "parents": [],
            "refoffsets": {
                "b0025": {
                    "endOffset": 20365,
                    "startOffset": 20362
                }
            },
            "secId": "s0005",
            "sentence": "In fact, CDC has reported a recent 114% increase in acute hepatitis B cases in Kentucky, Tennessee, and West Virginia associated with injection drug use stemming from the ongoing opioid epidemic [5].",
            "startOffset": 20167,
            "title": "Introduction"
        },
        {
            "endOffset": 24263,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "SPR was defined as the proportion of participants with antibody to hepatitis B surface antigen [anti-HBs] \u2265 10 mIU/mL.",
            "startOffset": 24145,
            "title": "Key trial objectives"
        },
        {
            "endOffset": 27919,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Assuming a 10% non-completion rate, at least 413 participants were to be enrolled in the study.",
            "startOffset": 27824,
            "title": "Statistical methods"
        },
        {
            "endOffset": 35989,
            "parents": [],
            "secId": "s0065",
            "sentence": "In addition to participants with diabetes, HBsAg-1018 induced significantly higher SPRs than HBsAg-Eng in the total study population and in each pre-specified population including those who had historically demonstrated lower rates of seroprotection including older adults, men, obese individuals, and smokers.",
            "startOffset": 35679,
            "title": "Discussion"
        },
        {
            "endOffset": 19700,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 19699,
                    "startOffset": 19696
                }
            },
            "secId": "s0005",
            "sentence": "Worldwide, an estimated 257 million persons are living with chronic hepatitis B infection and an estimated 887,000 persons died in 2015 from complications of hepatitis B [1].",
            "startOffset": 19526,
            "title": "Introduction"
        },
        {
            "endOffset": 31624,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Younger age, BMI < 30 kg/m2, and shorter duration of diabetes were associated with higher SPRs.",
            "startOffset": 31529,
            "title": "Primary analysis"
        },
        {
            "endOffset": 32341,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "The SPR in the HBsAg-1018 group was 95.2% (4837/5080) and in the HBsAg-Eng was 80.7% (2094/2595) with a difference in SPRs of 14.5% (95% CI: 12.9, 16.2).",
            "startOffset": 32188,
            "title": "Secondary analyses"
        },
        {
            "endOffset": 20044,
            "parents": [],
            "refoffsets": {
                "b0020": {
                    "endOffset": 20043,
                    "startOffset": 20040
                }
            },
            "secId": "s0005",
            "sentence": "In the US, the Centers for Disease Control and Prevention (CDC) estimated there were approximately 21,900 new HBV infections in 2015 with the vast majority of cases occurring in adults [4].",
            "startOffset": 19855,
            "title": "Introduction"
        },
        {
            "endOffset": 39165,
            "parents": [],
            "secId": "s0070",
            "sentence": "No other conflicts were reported.",
            "startOffset": 39132,
            "title": "Conflict of interest statement"
        },
        {
            "endOffset": 34724,
            "parents": [],
            "secId": "s0065",
            "sentence": "A sensitivity analysis for the primary endpoint demonstrated that HBsAg-1018, younger age, lower BMI, and shorter duration of diabetes mellitus were each independently associated with seroprotection.",
            "startOffset": 34525,
            "title": "Discussion"
        },
        {
            "endOffset": 37101,
            "parents": [],
            "secId": "s0065",
            "sentence": "However, published data suggest that completion of a two-dose regimen over one month is likely to be higher than completion of a three-dose regimen over 6 months.",
            "startOffset": 36939,
            "title": "Discussion"
        },
        {
            "endOffset": 30799,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0045",
            "sentence": "Such characteristics for participants with diabetes mellitus were also generally balanced across the vaccine groups.",
            "startOffset": 30683,
            "title": "Demographic and baseline characteristics"
        },
        {
            "endOffset": 37581,
            "parents": [],
            "refoffsets": {
                "b0195": {
                    "endOffset": 37580,
                    "startOffset": 37576
                }
            },
            "secId": "s0065",
            "sentence": "For example, in a study of an STD clinic population of men who have sex with men, 64% received two or more doses and only 43% received all three doses of a vaccine even when administered on an accelerated 0, 1, 4 month schedule [39].",
            "startOffset": 37348,
            "title": "Discussion"
        },
        {
            "endOffset": 39131,
            "parents": [],
            "secId": "s0070",
            "sentence": "Lalith Akella and William Heyward were consultants to Dynavax.",
            "startOffset": 39069,
            "title": "Conflict of interest statement"
        },
        {
            "endOffset": 33897,
            "parents": [],
            "refoffsets": {
                "b0155": {
                    "endOffset": 33896,
                    "startOffset": 33892
                }
            },
            "secId": "s0065",
            "sentence": "For example, in 2010, an estimated 77.2% of 14 million individuals with diabetes 59 years of age and younger (10.8 million individuals) had not been vaccinated [31].",
            "startOffset": 33732,
            "title": "Discussion"
        },
        {
            "endOffset": 25830,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Participants were excluded from the trial if they: were pregnant, breastfeeding, or planning a pregnancy during the study; had a history of HBV infection or autoimmune disease; were taking chronic corticosteroid therapy; had previously received any hepatitis B vaccine (approved or investigational), DNA plasmid, or oligonucleotide; or had any condition that in the opinion of the investigator would interfere with compliance or interpretation of the study assessments.",
            "startOffset": 25361,
            "title": "Study population"
        },
        {
            "endOffset": 35531,
            "parents": [],
            "secId": "s0065",
            "sentence": "In addition, in the study by Van Der Meeren and colleagues, 57.4% of participants were obese while in this trial 72.5% of participants with type 2 diabetes were obese.",
            "startOffset": 35364,
            "title": "Discussion"
        },
        {
            "endOffset": 36535,
            "parents": [],
            "secId": "s0065",
            "sentence": "The SPR in the HBsAg-1018 group was 95% or higher in all pre-specified populations except for those with diabetes or 60 to 70 years of age.",
            "startOffset": 36396,
            "title": "Discussion"
        },
        {
            "endOffset": 19855,
            "parents": [],
            "refoffsets": {
                "b0010": {
                    "endOffset": 19779,
                    "startOffset": 19776
                },
                "b0015": {
                    "endOffset": 19854,
                    "startOffset": 19851
                }
            },
            "secId": "s0005",
            "sentence": "In the US, up to 2.2 million individuals are chronically infected with HBV [2] and an estimated 5000 individuals die from HBV complications each year [3].",
            "startOffset": 19701,
            "title": "Introduction"
        },
        {
            "endOffset": 27823,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "A sample size of 250 HBsAg-1018 participants and 125 HBsAg-Eng participants would provide 92% power to demonstrate noninferiority if the immune response was similar to a previous phase 3 study.",
            "startOffset": 27630,
            "title": "Statistical methods"
        },
        {
            "endOffset": 37684,
            "parents": [],
            "refoffsets": {
                "b0200": {
                    "endOffset": 37683,
                    "startOffset": 37679
                }
            },
            "secId": "s0065",
            "sentence": "Failure to complete a vaccine regimen has been reported to result in acute hepatitis B infection [40].",
            "startOffset": 37582,
            "title": "Discussion"
        },
        {
            "endOffset": 34336,
            "parents": [],
            "refoffsets": {
                "b0160": {
                    "endOffset": 34191,
                    "startOffset": 34187
                },
                "b0165": {
                    "endOffset": 34335,
                    "startOffset": 34331
                }
            },
            "secId": "s0065",
            "sentence": "Such limitations will make it difficult to achieve the recent call by the World Health Assembly [32] and by the US National Academies of Sciences, Engineering, and Medicine for eliminating viral hepatitis as a public health problem by 2030 [33].",
            "startOffset": 34091,
            "title": "Discussion"
        },
        {
            "endOffset": 34002,
            "parents": [],
            "refoffsets": {
                "b0120": {
                    "endOffset": 34001,
                    "startOffset": 33997
                }
            },
            "secId": "s0065",
            "sentence": "Little progress has been made; in 2015, an estimated 75.6% of such persons had not been vaccinated [24].",
            "startOffset": 33898,
            "title": "Discussion"
        },
        {
            "endOffset": 33667,
            "parents": [],
            "secId": "s0065",
            "sentence": "Alum-adjuvanted vaccines approved for the prevention of hepatitis B infection are highly effective in children but less so in adults.",
            "startOffset": 33534,
            "title": "Discussion"
        },
        {
            "endOffset": 37347,
            "parents": [],
            "secId": "s0065",
            "sentence": "Adherence is even more challenging in high risk populations.",
            "startOffset": 37287,
            "title": "Discussion"
        },
        {
            "endOffset": 28633,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "refoffsets": {
                "b0145": {
                    "endOffset": 28632,
                    "startOffset": 28628
                }
            },
            "secId": "s0035",
            "sentence": "The immunogenicity analyses consisted of computing the SPRs and 95% confidence intervals (CI) for each vaccine group using the two-sided Clopper-Pearson method [29].",
            "startOffset": 28468,
            "title": "Statistical methods"
        },
        {
            "endOffset": 38404,
            "parents": [],
            "secId": "s0065",
            "sentence": "HBsAg-1018 demonstrated significantly increased immune responses in adults with factors that reduce their immune response.",
            "startOffset": 38282,
            "title": "Discussion"
        },
        {
            "endOffset": 23056,
            "parents": [],
            "secId": "s0005",
            "sentence": "To evaluate immunogenicity in persons with diabetes recommended for routine vaccination by ACIP, the primary immunogenicity endpoint in this study was in participants with diabetes.",
            "startOffset": 22875,
            "title": "Introduction"
        },
        {
            "endOffset": 29181,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "For secondary objectives, if noninferiority between HBsAg-1018 and HBsAg-Eng was established, and the lower limit of the CI was greater than 0, the HBsAg-1018 SPR would be considered to be statistically significantly higher than the HBsAg-Eng SPR.",
            "startOffset": 28934,
            "title": "Statistical methods"
        },
        {
            "endOffset": 23545,
            "parents": [],
            "secId": "s0010",
            "sentence": "The study was conducted at 40 study sites in the US between April 2014 and October 2015.",
            "startOffset": 23457,
            "title": "Materials and methods"
        },
        {
            "endOffset": 34090,
            "parents": [],
            "secId": "s0065",
            "sentence": "Even when the alum-adjuvanted vaccines are administered, they have several limitations.",
            "startOffset": 34003,
            "title": "Discussion"
        },
        {
            "endOffset": 35212,
            "parents": [],
            "refoffsets": {
                "b0175": {
                    "endOffset": 35120,
                    "startOffset": 35116
                },
                "b0180": {
                    "endOffset": 35211,
                    "startOffset": 35207
                }
            },
            "secId": "s0065",
            "sentence": "The population of individuals with type 2 diabetes in this trial is likely more representative of those who need hepatitis B vaccination [35] than those enrolled in a study of HBsAg-Eng reported by Van Der Meeren and colleagues [36].",
            "startOffset": 34979,
            "title": "Discussion"
        },
        {
            "endOffset": 31528,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "The odds ratio for seroprotection between HBsAg-1018 and HBsAg-Eng was 4.95 (95% CI: 3.46, 7.07).",
            "startOffset": 31431,
            "title": "Primary analysis"
        },
        {
            "endOffset": 35679,
            "parents": [],
            "secId": "s0065",
            "sentence": "These differences in participants likely explain why the HBsAg-Eng SPR was lower in this trial than that reported by Van Der Meeren and colleagues.",
            "startOffset": 35532,
            "title": "Discussion"
        },
        {
            "endOffset": 32079,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "In the total population and pre-specified subpopulations, HBsAg-1018 induced significantly higher SPRs at week 24 than HBsAg-Eng at week 28 (Fig. 2).",
            "startOffset": 31930,
            "title": "Secondary analyses"
        },
        {
            "endOffset": 26612,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Participants in the HBsAg-Eng group received the FDA approved regimen of intramuscular injections at weeks 0, 4, and 24.",
            "startOffset": 26492,
            "title": "Study vaccines and administration"
        },
        {
            "endOffset": 24144,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Co-primary objectives comprised the overall safety of HBsAg-1018 with respect to clinically significant events and an immunogenicity objective to demonstrate the noninferiority of the seroprotection rate (SPR) of HBsAg-1018 compared with the SPR of HBsAg-Eng among adults with type 2 diabetes mellitus at 4 weeks following the last dose of HBsAg-Eng (week 28).",
            "startOffset": 23784,
            "title": "Key trial objectives"
        },
        {
            "endOffset": 22463,
            "parents": [],
            "secId": "s0005",
            "sentence": "HBsAg-1018 was licensed by the US Food and Drug Administration (FDA) for use in adults in the US on November 9, 2017.",
            "startOffset": 22346,
            "title": "Introduction"
        },
        {
            "endOffset": 30852,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0045",
            "sentence": "Participants had diabetes for a median of 8.0 years.",
            "startOffset": 30800,
            "title": "Demographic and baseline characteristics"
        },
        {
            "endOffset": 35363,
            "parents": [],
            "secId": "s0065",
            "sentence": "In that trial, the median time since diagnosis of diabetes was 2.6 years and in this trial, the median time since diagnosis of diabetes was 7.9 years.",
            "startOffset": 35213,
            "title": "Discussion"
        },
        {
            "endOffset": 25150,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "All immunogenicity endpoints are based on the previous phase 3 trials that showed that the peak SPR among persons with type 2 diabetes mellitus was at 28 weeks for both vaccines, and the peak SPR among those without diabetes was at 24 weeks for HBsAg-1018 and 28 weeks for HBsAg-Eng.",
            "startOffset": 24867,
            "title": "Key trial objectives"
        },
        {
            "endOffset": 23414,
            "parents": [],
            "secId": "s0010",
            "sentence": "This was a phase 3, observer-blinded, randomized, active-controlled (HBsAg-Eng) trial of the immunogenicity and safety of HBsAg-1018 in adults 18 to 70 years of age.",
            "startOffset": 23249,
            "title": "Materials and methods"
        },
        {
            "endOffset": 23761,
            "parents": [],
            "secId": "s0010",
            "sentence": "Written informed consent was obtained prior to enrollment.",
            "startOffset": 23703,
            "title": "Materials and methods"
        },
        {
            "endOffset": 36666,
            "parents": [],
            "secId": "s0065",
            "sentence": "In contrast, in the HBsAg-Eng group, SPRs were lower than 90% in all pre-specified populations except those 18 to 39 years of age.",
            "startOffset": 36536,
            "title": "Discussion"
        }
    ],
    "docId": "S0264410X17317917",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": "sjackson@alkahest.com",
                "first": "Sam",
                "initial": "S.",
                "last": "Jackson"
            },
            {
                "email": "josephlentino@radiantresearch.com",
                "first": "Joseph",
                "initial": "J.",
                "last": "Lentino"
            },
            {
                "email": "jameskopp@radiantresearch.com",
                "first": "James",
                "initial": "J.",
                "last": "Kopp"
            },
            {
                "email": "LindaMurray@radiantresearch.com",
                "first": "Linda",
                "initial": "L.",
                "last": "Murray"
            },
            {
                "email": "travisellison@radiantresearch.com",
                "first": "William",
                "initial": "W.",
                "last": "Ellison"
            },
            {
                "email": "MargaretRhee@radiantresearch.com",
                "first": "Margaret",
                "initial": "M.",
                "last": "Rhee"
            },
            {
                "email": "gshockey@crastudies.com",
                "first": "Gerald",
                "initial": "G.",
                "last": "Shockey"
            },
            {
                "email": "lalith.akella@statshopinc.com",
                "first": "Lalith",
                "initial": "L.",
                "last": "Akella"
            },
            {
                "email": "kerby@dynavax.com",
                "first": "Kimberly",
                "initial": "K.",
                "last": "Erby"
            },
            {
                "email": "william_heyward@yahoo.com",
                "first": "William L.",
                "initial": "W.L.",
                "last": "Heyward"
            },
            {
                "email": "rjanssen@dynavax.com",
                "first": "Robert S.",
                "initial": "R.S.",
                "last": "Janssen"
            },
            {
                "email": null,
                "first": "Michael",
                "initial": "M.",
                "last": "Adams"
            },
            {
                "email": null,
                "first": "David",
                "initial": "D.",
                "last": "Bolshoun"
            },
            {
                "email": null,
                "first": "Tami",
                "initial": "T.",
                "last": "Bruce"
            },
            {
                "email": null,
                "first": "Rita",
                "initial": "R.",
                "last": "Chuang"
            },
            {
                "email": null,
                "first": "Donna",
                "initial": "D.",
                "last": "DeSantis"
            },
            {
                "email": null,
                "first": "Thomas",
                "initial": "T.",
                "last": "Fiel"
            },
            {
                "email": null,
                "first": "William",
                "initial": "W.",
                "last": "Fitzgibbons"
            },
            {
                "email": null,
                "first": "David",
                "initial": "D.",
                "last": "Francyk"
            },
            {
                "email": null,
                "first": "Harry",
                "initial": "H.",
                "last": "Geisberg"
            },
            {
                "email": null,
                "first": "Son",
                "initial": "S.",
                "last": "Giep"
            },
            {
                "email": null,
                "first": "Narendra",
                "initial": "N.",
                "last": "Godbole"
            },
            {
                "email": null,
                "first": "Terry",
                "initial": "T.",
                "last": "Haas"
            },
            {
                "email": null,
                "first": "Stephen",
                "initial": "S.",
                "last": "Halpern"
            },
            {
                "email": null,
                "first": "Anthony",
                "initial": "A.",
                "last": "Inzerello"
            },
            {
                "email": null,
                "first": "William",
                "initial": "W.",
                "last": "Jennings"
            },
            {
                "email": null,
                "first": "Scott",
                "initial": "S.",
                "last": "Kaiser"
            },
            {
                "email": null,
                "first": "Jennifer",
                "initial": "J.",
                "last": "Kay"
            },
            {
                "email": null,
                "first": "William",
                "initial": "W.",
                "last": "Kirby"
            },
            {
                "email": null,
                "first": "Robert",
                "initial": "R.",
                "last": "Lending"
            },
            {
                "email": null,
                "first": "Peter",
                "initial": "P.",
                "last": "Levins"
            },
            {
                "email": null,
                "first": "Clifford",
                "initial": "C.",
                "last": "Molin"
            },
            {
                "email": null,
                "first": "Michael",
                "initial": "M.",
                "last": "Noss"
            },
            {
                "email": null,
                "first": "Larry",
                "initial": "L.",
                "last": "Kotek"
            },
            {
                "email": null,
                "first": "Michele",
                "initial": "M.",
                "last": "Reynolds"
            },
            {
                "email": null,
                "first": "Ernie",
                "initial": "E.",
                "last": "Riffer"
            },
            {
                "email": null,
                "first": "Douglas",
                "initial": "D.",
                "last": "Schumacher"
            },
            {
                "email": null,
                "first": "Randall",
                "initial": "R.",
                "last": "Severance"
            },
            {
                "email": null,
                "first": "Royce",
                "initial": "R.",
                "last": "Solano"
            },
            {
                "email": null,
                "first": "Albert",
                "initial": "A.",
                "last": "Tejada"
            },
            {
                "email": null,
                "first": "Leslie",
                "initial": "L.",
                "last": "Tharenos"
            },
            {
                "email": null,
                "first": "Martin",
                "initial": "M.",
                "last": "Throne"
            },
            {
                "email": null,
                "first": "Merle",
                "initial": "M.",
                "last": "Turner"
            },
            {
                "email": null,
                "first": "Thomas",
                "initial": "T.",
                "last": "Wolf"
            },
            {
                "email": null,
                "first": "Mark",
                "initial": "M.",
                "last": "Woodruff"
            },
            {
                "email": null,
                "first": null,
                "initial": null,
                "last": null
            }
        ],
        "doi": "10.1016/j.vaccine.2017.12.038",
        "firstpage": "668",
        "issn": "0264410X",
        "keywords": [
            "Diabetes mellitus",
            "Engerix-B",
            "HEPLISAV-B",
            "Hepatitis B vaccine",
            "Toll-like receptor 9"
        ],
        "lastpage": "674",
        "openaccess": "Full",
        "pub_year": 2018,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults"
    }
}